There are currently 69 clinical trials in Orange City, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical Research Group of Central Florida /ID# 240711, Mid Florida Hematology and Oncology Center, Pfizer Investigational Site and Mid Florida Hematology and Oncology Center ( Site 0067). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05403385
Recruiting
Part 1 of the study determines the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving specific first line treatments for Stage 3 or metastatic non-small cell lung cancer. Part 2 compares the efficacy of inupadenant to placebo when both are combined with carboplatin and pemetrexed for patients that progressed after receiving the same first line treatments for Stage 3 or metastatic non-small cell lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/20/2023
Locations: Mid-Florida Hematology & Oncology Centers, PA, Orange City, Florida
Conditions: Metastatic NSCLC, Stage III NSCLC
Register for Updates
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
NCT05577715
Recruiting
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Mid Florida Cancer Center - Orange City, Orange City, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
NCT05077709
Recruiting
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2023
Locations: Mid Florida Hematology and Oncology Center, Orange City, Florida
Conditions: Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
Register for Updates
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976
Recruiting
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2023
Locations: Research Site, Orange City, Florida
Conditions: Solid Tumor, NSCLC
Register for Updates
PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
NCT05697198
Recruiting
The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from individuals with advanced solid tumors. Examples of locally advanced and metastatic tumors include stage III and IV cancers (ex. lung, breast, all gastrointestinal malignancies, all gynecologic mali... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Clinical Site, Orange City, Florida
Conditions: Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
Register for Updates
A Study of ICP-192 in Patients With Advanced Solid Tumors
NCT04565275
Recruiting
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2023
Locations: Mid Florida Hematology and Oncology, Orange City, Florida
Conditions: Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Mid Florida Hematology and Oncology Center, Orange City, Florida
Conditions: Colorectal Cancer
Register for Updates
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
NCT01908192
Recruiting
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/10/2021
Locations: Medical Research Group of Central Florida, Orange City, Florida
Conditions: Schizophrenia
Register for Updates
Prospective US Radiofrequency SUI Trial
NCT04720352
Recruiting
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pa... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/19/2021
Locations: A Premier Medical Research of Florida, Orange City, Florida
Conditions: Urinary Incontinence, Stress
Register for Updates